-
Sawai Receives Approvals for Six Generic Drugs with 13 Strengths
-
Sawai Announces Listing of Five Generic Drugs with 11 Strengths
-
Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths
-
Sawai Announces Listing of Five Generic Drugs with Nine Strengths
-
Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-
-
Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
-
Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP
-
Sawai Receives Approvals for Four Generic Drugs with Eight Strengths
-
Upsher-Smith Launches Isotretinoin Capsules
-
Sawai Launches Eight Generic Drugs with 23 Strengths
-
Upsher-Smith and Rafarm Announce Launch of Moxifloxacin Ophthalmic Solution, USP 0.5%
-
Message from the Chairman and Group CEO
